VIDEO: Transfusion-dependent myelofibrosis has best anemia responses with luspatercept
Click Here to Manage Email Alerts
In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study he presented at ASCO Annual Meeting, examining the effect of luspatercept on patients with myelofibrosis suffering from anemia.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the parameters of his study on luspatercept (Reblozyl; Celgene, Bristol Myers Squibb), which examined four cohorts of patients and found that the patients with the best anemia responses were transfusion dependent and on ruxolitinib (Jakafi, Incyte).
“It can already guide the care of patients with myelofibrosis, who may not have an adequate response to [erythropoiesis-stimulating agents], or have limited other options to treat their anemia,” Gerds said.
Collapse
Read more about
Click Here to Manage Email Alerts